Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)

• Published in: Current controlled trials in cardiovascular medicine Vol. 21; no. 1; pp. 520 - 4
• Main Authors: Ye, Qingsong, Wang, Hua, Xia, Xia, Zhou, Chenliang, Liu, Zhiming, Xia, Zun-en, Zhang, Zhan, Zhao, Yang, Yehenala, Jun, Wang, Si, Zhou, Gangqiao, Hu, Ke, Wu, Bin, Wu, Chu-Tse, Wang, Songling, He, Yan
• Format: Journal Article
• Language: English
• Published: England BioMed Central 12.06.2020; BMC
• Subjects: Adolescent; Adult; Aged; Blood platelets; Blood pressure; Cholesterol; Clinical trials; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronaviruses; COVID-19; COVID-19 - therapy; COVID-19; randomised controlled trial; protocol; human dental pulp stem cells; dental stem cell banking; Cytokines; Cytomegalovirus; Dental pulp; Dental Pulp - cytology; Female; Hepatitis; Hospitalization; Humans; Intensive care; Laboratories; Letter; Lipoproteins; Lymphocytes; Male; Middle Aged; Neutrophils; Outcome Assessment, Health Care; Patients; Pneumonia; Proteins; Randomized Controlled Trials as Topic; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Stem Cell Transplantation - adverse effects; Stem Cell Transplantation - methods; Stem cells; Transplantation, Homologous; Ventilators; Young Adult; COVID-19; randomised controlled trial; protocol; human dental pulp stem cells; dental stem cell banking

To assess the safety and therapeutic effects of allogeneic human dental pulp stem cells (DPSCs) in treating severe pneumonia caused by COVID-19. This is a single centre, two arm ratio 1:1, triple blinded, randomized, placebo-controlled, parallel group, clinical trial. Twenty serious COVID-19 cases w...